ES2263405T3 - Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. - Google Patents
Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. Download PDFInfo
- Publication number
- ES2263405T3 ES2263405T3 ES05075369T ES05075369T ES2263405T3 ES 2263405 T3 ES2263405 T3 ES 2263405T3 ES 05075369 T ES05075369 T ES 05075369T ES 05075369 T ES05075369 T ES 05075369T ES 2263405 T3 ES2263405 T3 ES 2263405T3
- Authority
- ES
- Spain
- Prior art keywords
- hpv
- virus
- vol
- recombinant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002245 particle Substances 0.000 title claims abstract description 88
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 73
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 71
- 241000700605 Viruses Species 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 81
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 49
- 108091026890 Coding region Proteins 0.000 claims abstract description 25
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 21
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 21
- 230000001900 immune effect Effects 0.000 claims abstract description 16
- 230000000877 morphologic effect Effects 0.000 claims abstract description 8
- 210000002845 virion Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 208000015181 infectious disease Diseases 0.000 claims description 41
- 241000701447 unidentified baculovirus Species 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 39
- 229960005486 vaccine Drugs 0.000 claims description 27
- 241000238631 Hexapoda Species 0.000 claims description 21
- 210000004392 genitalia Anatomy 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 238000012546 transfer Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims description 2
- 229940031348 multivalent vaccine Drugs 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 61
- 241000283973 Oryctolagus cuniculus Species 0.000 description 50
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 40
- 238000001262 western blot Methods 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 27
- 206010059313 Anogenital warts Diseases 0.000 description 24
- 239000000427 antigen Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 238000003119 immunoblot Methods 0.000 description 20
- 230000002458 infectious effect Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 230000000890 antigenic effect Effects 0.000 description 18
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 18
- 208000009608 Papillomavirus Infections Diseases 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 210000000234 capsid Anatomy 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 201000010153 skin papilloma Diseases 0.000 description 11
- 241001428582 Human papillomavirus type 6 Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 208000000907 Condylomata Acuminata Diseases 0.000 description 9
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 229940042743 immune sera Drugs 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000013049 sediment Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000701589 Human papillomavirus type 6b Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000003953 foreskin Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004201 immune sera Anatomy 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 101100342726 Mus musculus Lats1 gene Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000020030 perry Nutrition 0.000 description 4
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101150071434 BAR1 gene Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 3
- 241000341657 Human papillomavirus type 18 Species 0.000 description 3
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 3
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229960002566 papillomavirus vaccine Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000006648 viral gene expression Effects 0.000 description 3
- 241000701814 Bovine papillomavirus type 2 Species 0.000 description 2
- 238000011537 Coomassie blue staining Methods 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 241000883306 Huso huso Species 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 229930185472 acuminatum Natural products 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 208000021145 human papilloma virus infection Diseases 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000005464 sample preparation method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091028690 C-myc mRNA Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000341810 Human papillomavirus type 5 Species 0.000 description 1
- 108700025391 Human papillomavirus type 6 L1 Proteins 0.000 description 1
- 101100372820 Human papillomavirus type 6b L1 gene Proteins 0.000 description 1
- 241000722343 Human papillomavirus types Species 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000829388 Mus musculus polyomavirus 1 Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000013320 baculovirus expression vector system Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 201000004303 plantar wart Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000001307 recurrent respiratory papillomatosis Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/028,517 US8062642B1 (en) | 1993-03-09 | 1993-03-09 | Production of papillomavirus capsid protein and virus-like particles |
| US28517 | 1993-03-09 | ||
| US20730994A | 1994-03-07 | 1994-03-07 | |
| US207309 | 1994-03-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2263405T1 ES2263405T1 (es) | 2006-12-16 |
| ES2263405T3 true ES2263405T3 (es) | 2011-04-20 |
Family
ID=26703787
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
| ES05075889T Expired - Lifetime ES2263406T3 (es) | 1993-03-09 | 1994-03-08 | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
| ES05075369T Expired - Lifetime ES2263405T3 (es) | 1993-03-09 | 1994-03-08 | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94912186T Expired - Lifetime ES2242955T4 (es) | 1993-03-09 | 1994-03-08 | Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral. |
| ES05075889T Expired - Lifetime ES2263406T3 (es) | 1993-03-09 | 1994-03-08 | Producción de la proteína de capside l1 del papilomavirus humano hpv-11 y partículas de tipo virus. |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP1588713B1 (enExample) |
| JP (4) | JPH08507685A (enExample) |
| AT (3) | ATE296111T1 (enExample) |
| AU (3) | AU688759C (enExample) |
| CA (1) | CA2157932C (enExample) |
| DE (9) | DE69434383T2 (enExample) |
| DK (2) | DK1618888T3 (enExample) |
| ES (3) | ES2242955T4 (enExample) |
| FR (1) | FR11C0022I2 (enExample) |
| LU (3) | LU91313I2 (enExample) |
| NL (3) | NL300265I2 (enExample) |
| PT (2) | PT1618888E (enExample) |
| WO (1) | WO1994020137A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000023I1 (de) | 1991-07-19 | 2007-08-09 | Univ Queensland St Lucia | Impfsstoff gegen Humanes Papillomavirus (typ 18) |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| AUPM358894A0 (en) * | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5888516A (en) * | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
| AUPM566794A0 (en) * | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| DE59511047D1 (de) * | 1994-10-07 | 2006-06-14 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| AU2003235191B2 (en) * | 1994-10-07 | 2006-09-21 | Loyola University Of Chicago | Papilloma virus-like particles, fusion proteins as well as processes for their production |
| AR004464A1 (es) * | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| JP3958360B2 (ja) * | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
| US5820870A (en) * | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| US5840306A (en) * | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| EP0863982B1 (en) * | 1995-11-15 | 2004-01-21 | Merck & Co., Inc. | Synthetic hpv11 virus-like particles |
| DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| US6908615B1 (en) | 1996-03-18 | 2005-06-21 | Merck & Co., Inc. | DNA encoding human papilloma virus type 18 |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| ATE256734T1 (de) * | 1996-10-04 | 2004-01-15 | Merck & Co Inc | Synthetische hpv16 virus-ähnliche partikel |
| CA2274474C (en) * | 1996-12-09 | 2008-07-22 | Steven Ludmerer | Synthetic hpv16 virus-like particles |
| US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
| US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
| DE19925199A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| DE19925235A1 (de) | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
| ATE490346T1 (de) * | 2000-09-18 | 2010-12-15 | Medimmune Llc | In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1425423B1 (en) | 2001-08-13 | 2010-06-23 | University of Rochester | Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| ES2356154T3 (es) | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006065166A1 (en) * | 2005-07-26 | 2006-06-22 | Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' | Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008082719A2 (en) | 2006-08-30 | 2008-07-10 | University Of Rochester | Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| ES2657392T3 (es) | 2006-09-26 | 2018-03-05 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
| LT2137210T (lt) | 2007-03-02 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Naujas būdas ir kompozicijos |
| BRPI0811016B1 (pt) * | 2007-04-29 | 2021-09-21 | Xiamen Innovax Biotech Co., Ltd. | Proteína li truncada do papiloma vírus humano tipo 16 |
| BRPI0815818A2 (pt) | 2007-04-29 | 2016-08-02 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | proteína l1 truncada do papiloma vírus humano tipo 18 |
| DK2910566T5 (en) | 2007-05-29 | 2016-11-07 | Univ Xiamen | Truncated L1 protein of human papillomavirus 11 |
| US8748127B2 (en) | 2007-05-29 | 2014-06-10 | Xiamen University | Truncated L1 protein of human papillomavirus type 6 |
| US20110091496A1 (en) * | 2008-01-19 | 2011-04-21 | Graham Barney S | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| ES2565846T3 (es) | 2008-05-26 | 2016-04-07 | Cadila Healthcare Limited | Vacuna combinada contra el sarampión-papiloma humano |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| GB0820822D0 (en) | 2008-11-13 | 2008-12-24 | Inst Catala D Oncologia | Novel product and processes |
| US20120115207A1 (en) * | 2009-04-03 | 2012-05-10 | Deutsches Krebsforschungszentrum | Enhanced production of papillomavirus-like particles with a modified baculovirus expression system |
| PT2437753T (pt) | 2009-06-05 | 2016-11-23 | Infectious Disease Res Inst | Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| ES2643498T3 (es) | 2010-04-08 | 2017-11-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Ensayo de células presentadoras de antígenos de linfocitos B |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| RS58868B1 (sr) | 2012-02-07 | 2019-08-30 | Infectious Disease Res Inst | Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih |
| BR112014023092A8 (pt) | 2012-03-18 | 2017-07-25 | Glaxosmithkline Biologicals Sa | Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit |
| SMT201800368T1 (it) | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| EP3711768A1 (en) | 2013-04-18 | 2020-09-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL310015B1 (en) | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| CN108885212B (zh) | 2016-02-22 | 2022-05-31 | 勃林格殷格翰维特梅迪卡有限公司 | 固定生物分子的方法 |
| EP4112638A1 (en) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
| JP7195147B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Ｐｅｇ化リポソームおよび使用方法 |
| WO2017210364A1 (en) | 2016-06-01 | 2017-12-07 | Infectious Disease Research Institute | Nanoalum particles containing a sizing agent |
| AU2018285694B2 (en) | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| AU2018330165B2 (en) | 2017-09-08 | 2025-07-17 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
| BR112021023726A2 (pt) | 2019-05-25 | 2022-02-15 | Infectious Disease Res Inst | Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante |
| WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| CN117222428A (zh) | 2021-02-11 | 2023-12-12 | 葛兰素史克生物有限公司 | Hpv疫苗生产 |
| AU2023336224A1 (en) | 2022-09-09 | 2025-03-27 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
| CN116375816B (zh) * | 2023-01-06 | 2023-09-05 | 北京康乐卫士生物技术股份有限公司 | 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956288A (en) * | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| NZ232913A (en) * | 1989-03-15 | 1992-08-26 | Gist Brocades Nv | Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations |
| DE122007000023I1 (de) | 1991-07-19 | 2007-08-09 | Univ Queensland St Lucia | Impfsstoff gegen Humanes Papillomavirus (typ 18) |
-
1994
- 1994-03-08 ES ES94912186T patent/ES2242955T4/es not_active Expired - Lifetime
- 1994-03-08 AU AU64436/94A patent/AU688759C/en not_active Expired
- 1994-03-08 DE DE69434383T patent/DE69434383T2/de not_active Expired - Lifetime
- 1994-03-08 DE DE1994634383 patent/DE122007000014I1/de active Pending
- 1994-03-08 DE DE05075889T patent/DE05075889T1/de active Pending
- 1994-03-08 DE DE69435331T patent/DE69435331D1/de not_active Expired - Lifetime
- 1994-03-08 AT AT94912186T patent/ATE296111T1/de active
- 1994-03-08 EP EP05075889A patent/EP1588713B1/en not_active Expired - Lifetime
- 1994-03-08 PT PT05075369T patent/PT1618888E/pt unknown
- 1994-03-08 DE DE122007000090C patent/DE122007000090I1/de active Pending
- 1994-03-08 JP JP6520236A patent/JPH08507685A/ja not_active Withdrawn
- 1994-03-08 DK DK05075369.8T patent/DK1618888T3/da active
- 1994-03-08 AT AT05075369T patent/ATE494005T1/de active
- 1994-03-08 DE DE69435332T patent/DE69435332D1/de not_active Expired - Lifetime
- 1994-03-08 DE DE122007000089C patent/DE122007000089I1/de active Pending
- 1994-03-08 WO PCT/US1994/002443 patent/WO1994020137A1/en not_active Ceased
- 1994-03-08 AT AT05075889T patent/ATE492289T1/de not_active IP Right Cessation
- 1994-03-08 EP EP05075369A patent/EP1618888B1/en not_active Expired - Lifetime
- 1994-03-08 DK DK94912186T patent/DK0688227T3/da active
- 1994-03-08 EP EP94912186A patent/EP0688227B1/en not_active Expired - Lifetime
- 1994-03-08 ES ES05075889T patent/ES2263406T3/es not_active Expired - Lifetime
- 1994-03-08 ES ES05075369T patent/ES2263405T3/es not_active Expired - Lifetime
- 1994-03-08 CA CA2157932A patent/CA2157932C/en not_active Expired - Lifetime
- 1994-03-08 DE DE05075369T patent/DE05075369T1/de active Pending
- 1994-03-08 DE DE201112100018 patent/DE122011100018I1/de active Pending
- 1994-03-08 PT PT94912186T patent/PT688227E/pt unknown
-
2006
- 2006-10-11 JP JP2006277056A patent/JP4486075B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-21 NL NL300265C patent/NL300265I2/nl unknown
- 2007-02-21 LU LU91313C patent/LU91313I2/fr unknown
- 2007-03-07 AU AU2007201005A patent/AU2007201005B2/en not_active Expired
- 2007-03-07 AU AU2007201006A patent/AU2007201006B2/en not_active Expired
- 2007-12-14 LU LU91391C patent/LU91391I2/fr unknown
- 2007-12-14 LU LU91392C patent/LU91392I2/fr unknown
- 2007-12-14 NL NL300310C patent/NL300310I1/nl unknown
- 2007-12-14 NL NL300309C patent/NL300309I2/nl unknown
-
2010
- 2010-02-05 JP JP2010023691A patent/JP5386392B2/ja not_active Expired - Lifetime
- 2010-02-05 JP JP2010023690A patent/JP5306251B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-04 FR FR11C0022C patent/FR11C0022I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2263405T3 (es) | Producción de proteína de capside del papilomavirus humano y partículas de tipo virus. | |
| ES2279020T3 (es) | Vacuna contra el papilomavirus humano. | |
| Pastrana et al. | NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16 | |
| NO328128B1 (no) | Antigenisk formulering som omfatter et humant papillomaviruskapsomer for anvendelse som en vaksine, samt anvendelse derav for fremstilling av en farmasoytisk sammensetning for behandling og forebygging av HPV infeksjon og tilstander beslektet dermed. | |
| US6153201A (en) | Oral immunization with papillomavirus virus-like particles | |
| US8062642B1 (en) | Production of papillomavirus capsid protein and virus-like particles | |
| US7182947B2 (en) | Papillomavirus truncated L1 protein and fusion protein constructs | |
| JP2006507797A (ja) | Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法 | |
| Kuck et al. | Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly | |
| ES2237913T3 (es) | Medicamento para prevenir o tratar tumores especificos del virus del papiloma. | |
| HK1082206B (en) | Production of human papillomavirus capsid protein and virus-like particles | |
| HK1082196B (en) | Production of human papillomavirus hbv-11 capsid protein l1 and virus-like particles | |
| WO2005097987A1 (ja) | 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原 |